Major French study confirms non-inferiority of Avastin versus Lucentis
A multicentre French study comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that both drugs were comparable in terms of clinical efficacy for the treatment of neovascular age-related macular degeneration (AMD).
Presenting the results of the Group d’Evaluation Français Avastin versus Lucentis (GEFAL) study at the 13th EURETINA Congress, Laurent Kodjikian MD of the University Hospital of Lyon, said that the outcomes are in line with those of the Comparison of AMD Treatment Trial (CATT) published in 2012.
The GEFAL study was a prospective, double-masked, randomised study conducted in 38 public and private-sector French ophthalmology centres from June 2009 to November 2011.
Latest Articles
Organising for Success
Professional and personal goals drive practice ownership and operational choices.
Update on Astigmatism Analysis
Is Frugal Innovation Possible in Ophthalmology?
Improving access through financially and environmentally sustainable innovation.
iNovation Innovators Den Boosts Eye Care Pioneers
New ideas and industry, colleague, and funding contacts among the benefits.
José Güell: Trends in Cornea Treatment
Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.
Making IOLs a More Personal Choice
Surgeons may prefer some IOLs for their patients, but what about for themselves?
Need to Know: Higher-Order Aberrations and Polynomials
This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.
Never Go In Blind
Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.